• N3-kethoxal: Precision RNA Structure Probing & DNA Mapping

  2026-06-04

  N3-kethoxal (3-(2-azidoethoxy)-1,1-dihydroxybutan-2-one) revolutionizes RNA secondary structure probing and genomic mapping of accessible DNA with unmatched selectivity for unpaired guanine bases. Its membrane-permeable, azide-functionalized design streamlines bioorthogonal labeling workflows in both in vitro and in vivo systems.

• D-Luciferin Sodium Salt: Precision Firefly Luciferase Substr

  2026-06-04

  Harness the power of D-Luciferin sodium salt for sensitive, real-time monitoring of cell viability, metabolism, and gene expression. Discover practical protocol enhancements, troubleshooting strategies, and the latest innovations driving next-generation oncology and immunotherapy research.

• Anlotinib Inhibits Angiogenesis via VEGFR2, PDGFRβ, and FGFR

  2026-06-03

  This study demonstrates that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly suppresses angiogenesis by targeting VEGFR2, PDGFRβ, and FGFR1 signaling. These findings provide mechanistic evidence for its superior anti-angiogenic activity compared to established inhibitors, supporting its application in cancer research and experimental angiogenesis models.

• AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Metabol

  2026-06-03

  This study reveals a double-positive feedback loop between AMPK and SQSTM1/p62 during metabolic stress, leading to coordinated activation of AMPK and NRF2-driven antioxidant defenses. These insights clarify the molecular basis for co-occurring STK11 and KEAP1 mutations in lung cancer and establish new directions for targeting lysosomal and metabolic signaling.

• Patient-Derived Gastric Cancer Assembloids Reveal Microenvir

  2026-06-02

  This study introduces a patient-derived gastric cancer assembloid system that integrates matched tumor organoids with stromal cell subpopulations, closely mimicking the complexity of primary tumors. The model demonstrates that stromal components significantly influence gene expression and drug sensitivity, offering a physiologically relevant platform for personalized therapy discovery and resistance mechanism studies.

• Redox Precision: NADH as a Strategic Lever in Translational

  2026-06-02

  Explore how reduced nicotinamide adenine dinucleotide (NADH) is redefining translational research. This thought-leadership article synthesizes mechanistic insights, experimental strategies, and competitive positioning to help researchers harness NADH for disease modeling, mitochondrial electron transport chain research, and next-generation therapies. Built on peer-reviewed evidence and advanced product standards like APExBIO’s NADH (CAS 58-68-4), this guide elevates the conversation from routine protocols to strategic redox innovation.

• Eicosapentaenoic Acid: Omega-3 Fatty Acid Protocols & Insigh

  2026-06-01

  Eicosapentaenoic Acid (EPA) stands out as an advanced omega-3 fatty acid tool for cardiovascular and immunomodulatory research. This article delivers hands-on protocol guidelines, troubleshooting, and evidence-based innovations to help bench scientists achieve reproducible, high-impact results with APExBIO's EPA.

• Influenza Hemagglutinin (HA) Peptide: Elevating Epitope Tag

  2026-06-01

  The Influenza Hemagglutinin (HA) Peptide stands out as a gold-standard epitope tag for protein detection and purification, offering unmatched solubility and competitive elution performance. APExBIO’s A6004 product empowers advanced immunoprecipitation, high-sensitivity interaction mapping, and robust troubleshooting capabilities for modern molecular biology labs.

• BKT140 (BL-8040): Transforming CXCR4 Inhibition in Tumor Mic

  2026-05-31

  Explore how BKT140 (BL-8040) is redefining CXCR4-targeted oncology by enabling advanced interrogation of tumor microenvironment dynamics, stem cell mobilization, and apoptosis in cancer cells. This article delivers unique protocol insights and bridges mechanistic understanding with translational research applications.

• CXCR4-Targeted Theranostics in Lymphoma: Imaging and Therapy

  2026-05-30

  This review details recent advances in CXCR4-targeted imaging and therapeutic strategies for lymphoma, emphasizing the biological rationale for CXCR4 as a diagnostic and therapeutic target. Integrating molecular imaging agents and targeted antagonists, the study highlights how these approaches can personalize and improve lymphoma management.

• Phosphatase Inhibitor Cocktail 1: Precision Tools for Phosph

  2026-05-29

  Explore how Phosphatase Inhibitor Cocktail 1 (100X in DMSO) enables uncompromised protein phosphorylation preservation for advanced phosphoproteomic analyses. This in-depth article uniquely integrates mechanistic insight, translational impact, and protocol optimization for researchers targeting complex signaling pathways.

• AT-406 (SM-406) and the Next Wave of Apoptosis Pathway Modul

  2026-05-29

  This article provides translational researchers with a strategic, mechanistic, and forward-looking perspective on how AT-406 (SM-406) enables precise modulation of apoptosis pathways in cancer cells. By integrating the latest structural insights into death receptor signaling, evaluating experimental validation, and contextualizing competitive differentiation, we outline how AT-406 is advancing the field beyond standard inhibitor paradigms and shaping the future of translational oncology.

• Moxifloxacin: Fluoroquinolone Antibiotic for Advanced Toxici

  2026-05-28

  Moxifloxacin, a broad-spectrum fluoroquinolone antibiotic, is redefining in vitro and in vivo research through its unique mechanistic action on DNA gyrase and dose-dependent effects on cell viability and metabolism. This article delivers actionable workflows, protocol optimization, and practical troubleshooting, empowering researchers to harness Moxifloxacin for high-impact studies in antibiotic toxicity, cellular proliferation, and metabolic response.

• WY-14643 (Pirinixic Acid): PPARα Agonist in Tumor Microenvir

  2026-05-28

  Explore the unique role of WY-14643 (Pirinixic Acid) as a selective PPARα agonist in modulating the tumor microenvironment, with a focus on recent mechanistic insights and advanced applications in metabolic and oncology research. This cornerstone article delivers distinct, evidence-based guidance beyond standard metabolic disorder studies.

• Strategic Use of Z-VAD-FMK to Decipher Apoptosis and PANopto

  2026-05-27

  This thought-leadership article empowers translational researchers to navigate the evolving landscape of programmed cell death, spotlighting Z-VAD-FMK as a crucial mechanistic probe. We dissect the interplay of apoptosis and lytic cell death, integrate new insights from recent PANoptosis research, and provide actionable protocol guidance, bridging foundational biology with advanced translational strategy.

455 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page